18.34
0.37 (2.06%)
| Penutupan Terdahulu | 17.97 |
| Buka | 18.05 |
| Jumlah Dagangan | 695,713 |
| Purata Dagangan (3B) | 3,601,627 |
| Modal Pasaran | 4,335,392,768 |
| Harga / Pendapatan (P/E TTM) | 67.93 |
| Harga / Pendapatan (P/E Ke hadapan) | 20.96 |
| Harga / Jualan (P/S) | 11.46 |
| Harga / Buku (P/B) | 18.80 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | 17.80% |
| Margin Operasi (TTM) | 33.08% |
| EPS Cair (TTM) | 0.270 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 78.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 1,300.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 48.03% |
| Nisbah Semasa (MRQ) | 7.09 |
| Aliran Tunai Operasi (OCF TTM) | 86.05 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 46.00 M |
| Pulangan Atas Aset (ROA TTM) | 19.89% |
| Pulangan Atas Ekuiti (ROE TTM) | 35.55% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | ADMA Biologics Inc | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.0 |
| Purata | 0.38 |
|
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.51% |
| % Dimiliki oleh Institusi | 91.78% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 26.00 (HC Wainwright & Co., 41.77%) | Beli |
| Median | 25.50 (39.04%) | |
| Rendah | 25.00 (Raymond James, 36.31%) | Beli |
| Purata | 25.50 (39.04%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 22.62 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 08 Nov 2024 | 26.00 (41.77%) | Beli | 22.62 |
| 14 Oct 2024 | 18.00 (-1.85%) | Beli | 16.37 | |
| Raymond James | 08 Nov 2024 | 25.00 (36.31%) | Beli | 22.62 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 07 Jan 2025 | Pengumuman | ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025 |
| 20 Dec 2024 | Pengumuman | ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility |
| 07 Nov 2024 | Pengumuman | ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update |
| 29 Oct 2024 | Pengumuman | ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |